MLLT1 and acute lymphoblastic leukemia: Three specific FGs account for 83.3% (KMT2A-AFF1 61.1%, KMT2A-MLLT4 11.1%, and KMT2A-MLLT1 11.1%) of all KMT2A fusions in ALL.